Stockscreener 앱 받기
7.26
4.60%
-0.35
시간 외 거래:
7.21
-0.05
-0.69%
전일 마감가:
$7.61
열려 있는:
$7.58
하루 거래량:
390.29K
Relative Volume:
1.46
시가총액:
$116.09M
수익:
$5.12M
순이익/손실:
$-67.00M
주가수익비율:
-4.9388
EPS:
-1.47
순현금흐름:
$-38.94M
1주 성능:
-8.62%
1개월 성능:
-15.58%
6개월 성능:
-13.49%
1년 성능:
+13.40%
1일 변동 폭
$7.205
$7.61
1주일 범위
$7.205
$8.27
52주 변동 폭
$3.28
$9.8212
Verrica Pharmaceuticals Inc Stock (VRCA) Company Profile
명칭
Verrica Pharmaceuticals Inc
전화
484-453-3300
주소
10 NORTH HIGH STREET, WEST CHESTER, PA
VRCA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VRCA
Verrica Pharmaceuticals Inc
|
7.26 | 121.68M | 5.12M | -67.00M | -38.94M | -1.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Verrica Pharmaceuticals Inc Stock (VRCA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-06 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-11-05 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-07-25 | 업그레이드 | Needham | Hold → Buy |
| 2023-03-22 | 개시 | Jefferies | Buy |
| 2023-02-13 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-05-25 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-05-14 | 개시 | RBC Capital Mkts | Outperform |
| 2020-12-24 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-06-30 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-24 | 개시 | Northland Capital | Outperform |
| 2020-03-24 | 개시 | Needham | Buy |
| 2019-02-21 | 개시 | H.C. Wainwright | Buy |
모두보기
Verrica Pharmaceuticals Inc 주식(VRCA)의 최신 뉴스
Verrica Pharmaceuticals (NASDAQ:VRCA) Upgraded to “Buy” at Wall Street Zen - Defense World
Market Fear: Is Verrica Pharmaceuticals Inc stock a value trapAnalyst Downgrade & Daily Chart Pattern Signals - baoquankhu1.vn
Trade Report: Is Verrica Pharmaceuticals Inc stock good for income investorsPortfolio Gains Summary & AI Based Trade Execution Alerts - baoquankhu1.vn
Verrica doses first patient in phase 3 wart trial, eyes major label expansion - MSN
Volume Recap: What is Life Time Group Holdings Incs P E ratio telling usJuly 2025 Gainers & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
How Much Upside is Left in Verrica Pharmaceuticals (VRCA)? Wall Street Analysts Think 97.11% - sharewise.com
Verrica Pharmaceuticals Reports Q4 2024 Growth and Pipeline Progress - MSN
Verrica Pharmaceuticals Appoints Dr. Noah Rosenberg as Chief Medical Officer - MSN
Will Verrica Pharmaceuticals Inc. stock see insider buyingTrade Analysis Report & High Win Rate Trade Alerts - Улправда
Verrica Doses First Patient in Phase 3 Wart Trial, Eyes Major Label Expansion - MyChesCo
Why Verrica Pharmaceuticals Inc. stock is favored by top institutionsJuly 2025 Snapshot & Free Safe Entry Trade Signal Reports - ulpravda.ru
Will Verrica Pharmaceuticals Inc. stock benefit from green energy trendsRisk Management & Free Daily Entry Point Trade Alerts - ulpravda.ru
Will Verrica Pharmaceuticals Inc. (1NE) stock outperform benchmarks2025 Major Catalysts & Accurate Trade Setup Notifications - Улправда
Verrica doses first patient in phase 3 trial for common wart treatment - Investing.com Nigeria
First Patient Dosed in Phase 3 VP-102 Common Warts Program - Dermatology Times
Verrica Pharmaceuticals stock advances as TD Cowen reiterates Buy rating By Investing.com - Investing.com Nigeria
Verrica Pharmaceuticals stock advances as TD Cowen reiterates Buy rating - Investing.com India
Verrica Pharmaceuticals announces first patient dosed in phase 3 program - MarketScreener
Verrica Pharmaceuticals (VRCA) Begins Phase 3 Trials for Common Warts Treatment - GuruFocus
Verrica doses first patient in phase 3 trial for common wart treatment By Investing.com - Investing.com South Africa
Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts - Chartmill
Verrica reports high response rate in skin cancer study - MSN
Verrica Pharmaceuticals adds Caligan Partner to board - MSN
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Short Interest Update - Defense World
Verrica Pharmaceuticals Adds Caligan Partner to Board - The Globe and Mail
Short Interest in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Decreases By 26.2% - MarketBeat
Verrica Pharmaceuticals appoints Charles Frantzreb to board and approves equity grants - Investing.com Canada
Verrica Pharmaceuticals appoints Charles Frantzreb to board and approves equity grants By Investing.com - Investing.com South Africa
Verrica Pharmaceuticals Appoints New Director - TradingView — Track All Markets
Verrica Pharmaceuticals Inc. Appoints Charles Frantzreb as Director, Effective December 26, 2025 - marketscreener.com
Can Verrica Pharmaceuticals Inc. stock reach $100 price targetHigh Yield Income Stocks & Low Cost Portfolio Tips - bollywoodhelpline.com
Verrica Pharmaceuticals (VRCA) Stock Price, Quote, News & History - Benzinga
Verrica Pharmaceuticals upgraded to buy from hold at Brookline - MSN
Gains Report: Can Verrica Pharmaceuticals Inc. stock reach $100 price targetJuly 2025 Reactions & Entry Point Confirmation Signals - Улправда
Is Verrica Pharmaceuticals Inc. stock a safe buy before earningsTrade Analysis Report & AI Optimized Trading Strategy Guides - Улправда
Will Verrica Pharmaceuticals Inc. stock pay special dividendsQuarterly Performance Summary & AI Powered Market Entry Strategies - Улправда
With Verrica Pharmaceuticals Stock Surging, Have You Considered The Downside? - Trefis
Can Verrica Pharmaceuticals Inc. stock surprise with earnings upsideJuly 2025 Outlook & Verified Swing Trading Watchlists - Улправда
Verrica Pharmaceuticals (FRA:1NE0) EV-to-OCF : -4.47 (As of Dec. 19, 2025) - GuruFocus
Can Verrica Pharmaceuticals Inc. stock weather global recessionJuly 2025 Chart Watch & Smart Investment Allocation Tips - Улправда
Is Verrica Pharmaceuticals Inc. stock supported by innovation pipelineJuly 2025 Trade Ideas & High Accuracy Investment Entry Signals - Улправда
Is Verrica Pharmaceuticals Inc. stock a buy on dipsJuly 2025 Highlights & AI Powered Trade Plan Recommendations - Улправда
Will Verrica Pharmaceuticals Inc. (1NE) stock boost dividends furtherMarket Sentiment Review & Reliable Entry Point Alerts - DonanımHaber
Verrica Pharmaceuticals (NASDAQ:VRCA) Rating Increased to Buy at Brookline Capital Management - Defense World
Brookline Capital upgrades Verrica Pharmaceuticals (VRCA) - MSN
Aug Drivers: Will Verrica Pharmaceuticals Inc. stock see insider buyingMarket Sentiment Review & Weekly Top Gainers Alerts - Улправда
Is Verrica Pharmaceuticals Inc. (1NE) stock undervalued after correction2025 Sector Review & Verified Momentum Stock Alerts - Улправда
Verrica Pharmaceuticals (NASDAQ:VRCA) Stock Rating Upgraded by Brookline Capital Management - MarketBeat
Verrica Pharmaceuticals (VRCA) Receives Upgrade from Brookline C - GuruFocus
Verrica Pharmaceuticals Inc (VRCA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Verrica Pharmaceuticals Inc 주식 (VRCA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Kirby John J. | Interim CFO |
Nov 25 '25 |
Buy |
4.24 |
3,536 |
15,001 |
8,962 |
| Zawitz David | Chief Operating Officer |
Nov 25 '25 |
Buy |
4.24 |
10,000 |
42,425 |
21,000 |
| Rieger Jayson | CEO and President |
Nov 25 '25 |
Buy |
4.24 |
94,311 |
400,114 |
182,593 |
| Manning Paul B | Director |
Nov 25 '25 |
Buy |
4.24 |
2,750,762 |
11,670,108 |
3,348,372 |
| Manning Paul B | Director |
Nov 25 '25 |
Buy |
4.24 |
1,375,380 |
5,835,050 |
3,958,189 |
| Hayes Christopher G. | CHIEF LEGAL OFFICER |
Mar 17 '25 |
Sale |
0.65 |
4,315 |
2,805 |
176,458 |
4.73%
0.92%
자본화:
|
볼륨(24시간):